FIRST APPLICATION OF MINIMAL RESIDUAL DISEASE ANALYSIS IN SPLENIC MARGINAL ZONE LYMPHOMA TRIALS: PRELIMINARY RESULTS FROM BRISMA/IELSG36 PHASE II STUDY. (12th June 2019) - Ferrero, S.; Ladetto, M.; Beldjord, K.; Drandi, D.; Stelitano, C.; Bernard, S.; Castagnari, B.; Bouabdallah, K.; Cesaretti, M.; Alvarez, I.; Gressin, R.; Ponzoni, M.; et al.